艾美疫苗(06660.HK)一度升逾10% 公司指不排除進軍歐美市場
艾美疫苗(06660.HK)今日高開1.34%,最高見7.43元,升10.73%。現報7.23元,升7.75%,成交94.78萬股,涉資676.49萬元。
公司上周五(22日)舉辦2023年投資者開放日活動,向近40家投資機構重點介紹集團即將上市的重磅創新疫苗產品及其生產車間建設情況,以及集團產品管線佈局和規劃。公司指,在實施國際化過程中,目前主要開發的國際市場集中在東南亞、非洲、南美、中東等地區,今後不排除進軍歐美市場的可能。數據顯示該產品目前全球市場缺口大約為1.2億劑,有信心在滿足國內需求之後逐步滿足國際需求。
另外,公司的無血清迭代狂犬疫苗、13價肺炎結合疫苗、23價肺炎多糖疫苗預計於明年申請註冊上市。預計再過5年,將會擁有超過20款疫苗產品獲批上市。隨著新產品的陸續上市,業務有望迎來新的增長點。(cy/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.